Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Surface Oncology, Inc.

https://www.surfaceoncology.com

Latest From Surface Oncology, Inc.

Compugen Still Confident Of Its TIGIT Strategy Despite Roche’s Setbacks

The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.

Commercial Clinical Trials

Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL

NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.

ImmunoOncology Cancer

China’s Insatiable Appetite For Latest Therapies Prompts Ex-Exec To Take New Journey

After immuno-oncology, cell therapies such as CAR-Ts have attracted millions of dollars of funding in China and one former executive is now sailing into the largely uncharted waters of natural killer cells.

China Companies

GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone

GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.

Cancer Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register